New Preclinical Study Shows Antibody Therapy Could Offer Treatment Path for Genetic Form of ALS

New preclinical research shows promise for a potential treatment pathway aimed at slowing the disease process and extending survival in patients with ALS, often called Lou Gehrig’s disease, an insidious neurological condition.

The research by University of Florida neurogeneticists Laura Ranum, Ph.D., and Lien Nguyen, Ph.D.; Neurimmune; Biogen; and collaborators at Johns Hopkins University shows that targeting a specific mutant protein in the brain with a human-derived antibody can lower neuroinflammation, slow neurodegeneration and lengthen survival in the most common genetic form of amyotrophic lateral sclerosis, or ALS, and frontotemporal dementia, or FTD.

Learn more about New Preclinical Study Shows Antibody Therapy Could Offer Treatment Path for Genetic Form of ALS.